BriaCell Therapeutics Corp.
No enriched coverage for $BCTX in the last 7 days.
No SEC Form 4 filings for $BCTX in the last 30 days.
BriaCell Therapeutics (Nasdaq: BCTX, BCTXL; TSX: BCT) said it arranged manufacturing capacity with FUJIFILM Biotechnologies California to support the remainder of its pivotal Phase 3 study and potential future commercialization of Bria-IMT, an allogeneic cell therapy. Bria-IMT is being tested in metastatic breast cancer with an immune checkpoint inhibitor (NCT06072612).
BriaCell Therapeutics (Nasdaq: BCTX, BCTXL; TSX: BCT) said it hired Charles River Associates (CRA) and Kaleio to support commercial strategy, market-access evaluation, and brand planning for Bria-IMT. Bria-IMT is in an ongoing pivotal Phase 3 study for metastatic breast cancer and is not yet approved.
BriaCell Therapeutics reported positive ASCO 2026 data for Bria-IMT in heavily pretreated metastatic breast cancer. Phase 2 results cited by the company showed 55% survival beyond 1 year and 27% beyond 2 years with the Phase 3-selected regimen; TWiST and quality-of-life analyses from the ongoing Phase 3 Bria-ABC study indicated meaningful benefit with no unexpected safety signals.
Recent BCTX coverage spans financial news, market movers and sector analysis.
Securing CDMO manufacturing capacity reduces execution risk for Bria-IMT’s Phase 3 and potential commercialization, a positive operational catalyst for BCTX.
Commercial-readiness workstreams were added for an unapproved Phase 3 asset, which can modestly improve perceived commercialization planning but does not change clinical/regulatory timelines.
ASCO posters strengthen the clinical efficacy/tolerability narrative for Bria-IMT and support Phase 3 Bria-ABC continuation with validated biomarkers.
Ongoing Phase 3 safety review cleared without modifications, reducing near-term clinical risk and supporting continued trial execution.
The recent $30 million public offering by BriaCell Therapeutics indicates strong investor confidence and potential for growth. The bullish sentiment (score: 0.427) suggests upward price movement in the near term.
alphai scores every news story that mentions BCTX with an AI model for sentiment and relevance, and aggregates insider trades from BriaCell Therapeutics Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BriaCell Therapeutics (Nasdaq: BCTX, BCTXL; TSX: BCT) said it arranged manufacturing capacity with FUJIFILM Biotechnologies California to support the remainder of its pivotal Phase 3 study and potential future commercialization of Bria-IMT, an allogeneic cell therapy. Bria-IMT is being tested in metastatic breast cancer with an immune checkpoint inhibitor (NCT06072612).
3 min readBriaCell Therapeutics (Nasdaq: BCTX, BCTXL; TSX: BCT) said it hired Charles River Associates (CRA) and Kaleio to support commercial strategy, market-access evaluation, and brand planning for Bria-IMT. Bria-IMT is in an ongoing pivotal Phase 3 study for metastatic breast cancer and is not yet approved.
3 min readBriaCell Therapeutics reported positive ASCO 2026 data for Bria-IMT in heavily pretreated metastatic breast cancer. Phase 2 results cited by the company showed 55% survival beyond 1 year and 27% beyond 2 years with the Phase 3-selected regimen; TWiST and quality-of-life analyses from the ongoing Phase 3 Bria-ABC study indicated meaningful benefit with no unexpected safety signals.
6 min readBriaCell Therapeutics (Nasdaq: BCTX; TSX: BCT) said its independent Data Safety Monitoring Board reviewed safety data from its pivotal Phase 3 Bria-ABC trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer and raised no safety concerns, recommending continuation without modifications. The DSMB issued its sixth consecutive positive recommendation; the study is under FDA Fast Track.
2 min readBriaCell Therapeutics Corp., a clinical-stage biotechnology company, announced the closing of a public offering that generated approximately US$30 million in gross proceeds. The offering included 5,366,726 units, each consisting of one common share (or pre-funded warrant) and one warrant, sold at US$5.59 per unit. The net proceeds will be used for working capital, general corporate purposes, and advancing the company's business objectives.
2 min readBriaCell has announced the addition of Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University to its Phase 3 metastatic breast cancer study. This expansion significantly grows its network to 79 clinical sites across 23 US states, aiming to accelerate patient enrollment. The company anticipates reporting top-line data as early as H1-2026 for its Bria-IMT treatment.
4 min readPHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( Nasdaq: BCTX, BCTXW, BCTXZ ) ( TSX: BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ...
4 min readPHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( NASDAQ:BCTX, BCTXW ) ) ( TSX:BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to ...
2 min readPHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( Nasdaq: BCTX, BCTXW ) ( TSX: BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to ...
3 min readNext generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both Bria-BRES+™ ( breast cancer ) and Bria-PROS+™ ( prostate cancer )
2 min read
